Table 1 Supplementary clinical information of PDOs donor.
Sample ID | Tumor stage | Type of treatments | Clinical outcome | Mutation | ||
|---|---|---|---|---|---|---|
KRas | Nras | Braf | ||||
P1 | T3N0M0 | Surgery | Survival | Wild | Wild | Wild |
P2 | T3N2M0 | Postoperative chemotherapy (XELOX) | Survival | Wild | Wild | Wild |
P3 | T3N0M0 | Surgery | Survival | Not detected | Not detected | Not detected |
P4 | T3N1M1 | mFOLFOX6 + cetuxima, liver metastases resection, postoperative chemotherapy (XELOX) | Recurrence | Wild | Wild | Wild |
P5 | T3N1M1 | FOLFOX, liver metastases resection, Postoperative chemotherapy (XELOX) | Survival | exon 2 mutation | Wild | Wild |
P6 | T4N1M1 | mFOLFOX6, liver metastases resection, Postoperative chemotherapy (XELOX) | Recurrence | exon 2 mutation | Wild | Wild |
P7 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | Wild | Wild | Wild |
P8 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | Not detected | Not detected | Not detected |
P9 | T3N0M0 | Surgery | Survival | Wild | Wild | Wild |
P10 | T3N0M0 | Surgery | Survival | Not detected | Not detected | Not detected |
P11 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | Wild | Wild | Wild |
P12 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | exon 2 mutation | Wild | Wild |
P13 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | Not detected | Not detected | Not detected |
P14 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | Not detected | Not detected | Not detected |
